Supplementary Material

Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases

Andrew GB Thompson[1], Prodromos Anastasiadis[1], Ronald Druyeh[1], Ines Whitworth[1], Akin Nihat[1,2], Tze How Mok[1,2], Peter Rudge[1,2], Jonathan DF Wadsworth[1], Jonathan Rohrer[3], Jonathan Schott [3], Amanda Heslegrave[4], Henrik Zetterberg[4,5,6], John Collinge[1,2], Graham S Jackson[1], Simon Mead[1,2].

Contents

Supplementary Table 1: Linear regression for baseline log-tau and log-NfL in sCJD, with age, gender, PRNP codon 129 genotype, MRC Score and MRC Slope as covariates 2

Supplementary Figure 1. Distribution of rate of change in plasma tau and NfL between all serial sample pairs in sCJD 3

Supplementary Table 2A: Linear mixed effects model for change in log-tau over time, with random effects by individual 4

Supplementary Table 2B: Linear mixed effects model for change in Tau (log-tau) with change in MRC Scale, with random effects by individual 5

Supplementary Table 2C: Linear mixed effects model for change in NfL (log-NfL) over time, with random effects by individual 6

Supplementary Table 2D: Linear mixed effects model for change in NfL (log-NfL) with change in MRC Score, with random effects by individual 7

Supplementary Table 3. Effect of PrP^{Sc} type on plasma tau and NfL levels 8

Supplementary Note 1: Predicting clinical progression in sCJD using baseline biomarker results 9

Supplementary Figure 2. Comparing plasma tau and plasma NfL (both shown on log scales) between PRNP mutations in symptomatic IPD 10

Supplementary Figure 3. Relationship of plasma tau and NfL to number of days from death in symptomatic IPD, including both cross-sectional and longitudinal datasets 11

Supplementary Figure 4. Relationship of plasma tau and NfL to number of days from death in iCJD and vCJD, including both cross-sectional and longitudinal datasets 12

References 13

Supplementary Table 1: Linear regression for baseline log-tau and log-NfL in sCJD, with age, gender, PRNP codon 129 genotype, MRC Score and MRC Slope as covariates

Log -tau

	Coef.	SE	t	p value	95% CI (Coef.)	
Age	-0.0006511	0.0024197	-0.27	0.788	-0.0054325	0.0041304
Gender	-0.0707005	0.0595624	-1.19	0.237	-0.1883966	0.0469956
Codon 129	-0.0425298	0.0457946	-0.93	0.355	-0.1330206	0.047961
MRC Score	-0.0128264	0.0064227	-2	0.048	-0.0255177	-0.000135
MRC Slope	**0.2777325**	**0.0388402**	**7.15**	**<0.001**	**0.2009838**	**0.3544812**
Constant	**0.8041434**	**0.182551**	**4.41**	**<0.001**	**0.4434202**	**1.164867**

Overall R-squared = 0.358

Log-NfL

	Coef.	SE	t	p value	95% CI (Coef.)	
Age	0.0057589	0.0022414	2.57	0.011	0.0013298	0.010188
Gender	0.0625685	0.0552005	1.13	0.259	-0.0465084	0.1716454
Codon 129	0.0959208	0.0425146	2.26	0.026	0.0119114	0.1799303
MRC Score	**-0.034434**	**0.0059151**	**-5.82**	**<0.001**	**-0.0461223**	**-0.0227458**
MRC Slope	0.0642922	0.0360644	1.78	0.077	-0.0069716	0.135556
Constant	**1.743891**	**0.1688592**	**10.33**	**<0.001**	**1.410223**	**2.077559**

Overall R-Squared = 0.359

Supplementary Figure 1. Distribution of rate of change in plasma tau and NfL between all serial sample pairs in sCJD

Plasma NfL tended to increase over time, and with increasing levels of functional impairment: in 63 serial sample pairs from 44 individuals, the median rate of change in plasma NfL was +2.88% per week (IQR +0.58% to 7.32%). Plasma tau also tended to increase over time, although this was more variable: in 60 sample pairs from 41 individuals the median rate of change was +2.37% per week (IQR -1.3% to +15%).



Supplementary Table 2A: Linear mixed effects model for change in log-tau over time, with random effects by individual

Mixed-effects REML regression — Number of samples = 101

Number of individuals = 41

Wald Chi2(6) = 14.60

Log restricted-likelihood = -39.616441 — Prob > Chi2 = 0.0236

Fixed effects		Coef.	SE	z	p value	95% CI (Coef.)	
Time (days from death)		-0.0001633	0.0001181	-1.38	0.167	-0.0003948	0.0000683
Age		0.0037123	0.0048443	0.77	0.443	-0.0057823	0.0132069
PRNP codon 129 genotype (relative to MV) effect on intercept							
	MM	-0.0254731	0.2012527	-0.13	0.899	-0.4199211	0.3689748
	VV	-0.0233208	0.1565643	-0.15	0.882	-0.3301812	0.2835396
PRNP codon 129 genotype (relative to MV) effect on slope (log-tau vs time)							
1	MM	0.0004924	0.000468	1.05	0.293	-0.0004248	0.0014096
3	VV	0.0032901	0.0013407	2.45	0.014	0.0006624	0.0059178
Constant		0.3564546	0.3058501	1.17	0.244	-0.2430005	0.9559097

Random effects (by individual)

Parameters		Estimate	SE	95% CI (Estimate)	
SD (Constant)		0.2124896	0.0472058	0.1374797	0.3284255
SD (Days from death)		7.79E-11	.	.	.
Residuals:	Independent				
By *PRNP* codon 129 genotype					
MM	sd(e)	0.3340261	0.1299548	0.1558172	0.7160533
MV	sd(e)	0.197673	0.0211525	0.1602739	0.2437992
VV	sd(e)	0.2275296	0.0508104	0.1468768	0.3524704

LR test vs. linear regression: Chi2(4) = 21.66 — Prob > Chi2 = 0.0002

Supplementary Table 2B: Linear mixed effects model for change in Tau (log-tau) with change in MRC Scale, with random effects by individual

Mixed-effects REML regression — Number of samples = 91

Group variable: cohortid — Number of individuals = 40

Wald Chi2(6) = 14.80

Log restricted-likelihood = -29.306071 — Prob > Chi2 = 0.0218

Fixed effects		Coef.	SE	z	p value	95% CI (Coef.)	
MRC Score		-0.0159666	0.0066046	-2.42	0.016	-0.0289114	-0.0030218
Age		-0.0027268	0.0043042	-0.63	0.526	-0.0111629	0.0057093
PRNP codon 129 genotype (relative to MV) effect on intercept							
	MM	0.3154141	0.3622733	0.87	0.384	-0.3946285	1.025457
	VV	0.2756725	0.1716547	1.61	0.108	-0.0607645	0.6121095
PRNP codon 129 genotype (relative to MV) effect on slope (log-tau vs time)							
1	MM	-0.0263727	0.0372293	-0.71	0.479	-0.0993407	0.0465953
3	VV	-0.0028959	0.0184395	-0.16	0.875	-0.0390367	0.0332448
Constant		0.8436671	0.276107	3.06	0.002	0.3025074	1.384827

Random effects (by individual)

Parameters		Estimate	SE	95% CI (Estimate)	
SD (Constant)		0.2040276	0.0477484	0.1289683	0.3227713
SD (MRC Score)		0.0043681	0.0202764	4.89E-07	39.03827
Residuals:	Independent				
By PRNP codon 129 genotype					
MM	sd(e)	0.4906119	0.1580161	0.2609657	0.9223436
MV	sd(e)	0.1970122	0.0249731	0.1536723	0.2525751
VV	sd(e)	0.2395811	0.0605531	0.1459872	0.3931789

LR test vs. linear regression: chi2(4) = 19.62 — Prob > Chi2 = 0.0006

Supplementary Table 2C: Linear mixed effects model for change in NfL (log-NfL) over time, with random effects by individual

Mixed-effects REML regression — Number of samples = 108

Group variable: cohortid — Number of individuals = 44

Wald Chi2(6) = 34.68

Log restricted-likelihood = -21.849083 — Prob > Chi2 = 0.0000

Fixed effects		Coef.	SE	z	p value	95% CI (Coef.)	
Time (days from death)		-0.0008608	0.0002032	-4.24	0	-0.0012592	-0.0004625
Age		-0.0123781	0.0050515	-2.45	0.014	-0.0222789	-0.0024773
PRNP codon 129 genotype (relative to MV) effect on intercept							
	MM	-0.1690149	0.1845158	-0.92	0.36	-0.5306592	0.1926294
	VV	0.2321624	0.1354934	1.71	0.087	-0.0333998	0.4977245
PRNP codon 129 genotype (relative to MV) effect on slope (log-tau vs time)							
1	MM	0.0002357	0.0005435	0.43	0.665	-0.0008296	0.001301
3	VV	-0.0027947	0.0010511	-2.66	0.008	-0.0048548	-0.0007346
Constant		3.106646	0.3247861	9.57	0	2.470077	3.743215

Random effects (by individual)

Parameters		Estimate	SE	95% CI (Estimate)	
SD (Constant)		0.2500583	0.0386523	0.1847007	0.3385432
SD (Days from death)		0.0004722	0.0001807	0.0002231	0.0009996
Residuals:	Independent				
By PRNP codon 129 genotype					
MM	sd(e)	0.2224403	0.062041	0.1287669	0.3842577
MV	sd(e)	0.1315952	0.0174293	0.1015083	0.1705998
VV	sd(e)	0.1403208	0.031528	0.0903379	0.2179588

LR test vs. linear regression: Chi2(4) = 41.98 — Prob > Chi2 = 0.0000

Supplementary Table 2D: Linear mixed effects model for change in NfL (log-NfL) with change in MRC Score, with random effects by individual

Mixed-effects REML regression — Number of samples = 90

Group variable: cohortid — Number of individuals = 40

Wald Chi2(6) = 30.58

Log restricted-likelihood = -6.8495749 — Prob > Chi2 = 0.0000

Fixed effects		Coef.	SE	z	p value	95% CI (Coef.)	
MRC Score		-0.0202391	0.0044915	-4.51	0	-0.0290423	-0.011436
Age		-0.0042519	0.0045535	-0.93	0.35	-0.0131767	0.0046728
PRNP codon 129 genotype (relative to MV) effect on intercept							
	MM	-0.0101468	0.2011561	-0.05	0.96	-0.4044056	0.3841119
	VV	0.1482622	0.16386	0.9	0.366	-0.1728975	0.4694219
PRNP codon 129 genotype (relative to MV) effect on slope (log-tau vs time)							
1	MM	-0.0173681	0.0188064	-0.92	0.356	-0.0542281	0.0194918
3	VV	-0.0041224	0.0158515	-0.26	0.795	-0.0351907	0.0269459
Constant		2.566831	0.2914613	8.81	0	1.995578	3.138085

Random effects (by individual)

Parameters		Estimate	SE	95% CI (Estimate)	
SD (Constant)		0.2487093	0.0343095	0.1897879	0.3259234
SD (MRC Score)		1.16E-13	.	.	.
Residuals:	Independent				
By PRNP codon 129 genotype					
MM	sd(e)	0.1982812	0.0703761	0.0988926	0.3975566
MV	sd(e)	0.1205778	0.0141177	0.0958529	0.1516802
VV	sd(e)	0.1938962	0.0475099	0.1199504	0.3134274

LR test vs. linear regression: chi2(4) = 50.42 — Prob > Chi2 = 0.0000

Supplementary Table 3. PrP^{Sc} type and plasma tau and NfL levels

A subset of sCJD patients in the study proceeded to post mortem examination and PrP^{Sc} types were determined as described previously[1]. The London classification[2,3] is different from a widely used consensus classification[4], in that Parchi type 1 and 2 are equivalent to London types 2 and 3 in that the London system divides Parchi type 1 into two types, 1 and 2. We found some evidence that plasma tau levels are higher in London MM type 2 (Parchi type 1) in keeping with the typical faster progression of this type.

Chart Label	c129	PrP^{Sc} Type (London)	PrP^{Sc} Type (Parchi)	n	Median Tau	Mann-Whitney U Test		Median NfL	Mann-Whitney U Test	
MM-2 (n=13)	MM	2	1	13	34.00	**Z**	2.571	118.26	**Z**	0.833
MM-3 (n=8)	MM	3	2	8	10.38	**p-value**	0.010	176.84	**p-value**	0.407
MV-2 (n=7)	MV	2	1	7	1.84	**Z**	0.635	123.06	**Z**	0.033
MV-3 (n=16)	MV	3	2	16	3.12	**p-value**	0.529	119.05	**p-value**	0.976
VV-2 (n=1)	VV	2	1	1	6.34	n/a		760.84	n/a	
VV-3 (n=8)	VV	3	2	8	5.46			178.28		

Supplementary Note 1: Predicting clinical progression in sCJD using baseline biomarker results

We explored whether baseline assessment of plasma tau or NfL concentration could help to predict subsequent rate of clinical disease progression in sCJD patients, and thereby have potential value for stratifying patients at enrolment to clinical trials. We added these baseline biomarker measures to the previously published linear mixed models of decline in MRC Scale[5], for those patients that had a sample tested in this study which was taken prior to, or at the time of, their enrolment to the clinical Cohort study: 98 patients in total. Models using untransformed biomarker concentration values, log-transformed values, and with truncation of outliers (values > 95th percentile set at the 95th percentile value, to prevent over-fitting to extreme numerical outliers), and including fixed effects for age and *PRNP* codon 129 genotype, were compared using Akaike Information Criterion (AIC).

For NfL, the best fitting model was that including log-transformed plasma NfL concentration (AIC=4767.4, compared with AIC=4781.2 for the model without baseline biomarkers as previously published). This showed an independent effect of MRC Scale on intercept ($p<0.001$), with higher baseline log plasma NfL predicting lower MRC Scale at enrolment. However, there was no independent effect on subsequent rate of change in MRC Scale over time. As MRC Scale at enrolment can be directly assessed in all patients, predicting this does not provide any additional clinical utility.

For tau, the best fitting model (AIC=4776.3, compared with AIC=4781.2 for the standard model) was that including untransformed plasma tau concentration. This showed an effect of baseline plasma tau on subsequent rate of decline in MRC Scale ($p=0.008$), but this appeared to be driven by outliers (a small number of patients with extremely high baseline tau and very rapid clinical decline), as it did not persist after truncation of plasma tau values > the 95th percentile ($p=0.659$). Exploring these models appeared to show a differential effect of baseline plasma tau on rate of decline in MRC Scale between different *PRNP* codon 129 genotypes. We therefore also explored modelling baseline plasma tau as a predictor separately within each codon 129 genotype. Within the MM group (31 patients), higher baseline concentrations of plasma tau were associated with more rapid subsequent decline in MRC Scale over time ($p<0.001$), and this persisted after truncation of values > 95th percentile ($p<0.001$), and was also present for log-transformed plasma tau concentration ($p<0.001$). In contrast there was no effect of baseline plasma tau on subsequent rate of clinical decline in the models for MV (n=43) or VV (n=24) patients. There may therefore be some additional predictive value if baseline plasma tau is included in predictive models in a specific subset of patients, but the overall benefit from adding this into existing models appears to be small.

Supplementary Figure 2. Comparing plasma tau and plasma NfL (both shown on log scales) between *PRNP* mutations in symptomatic IPD

We used the earliest available sample for all *PRNP* mutation carriers with symptomatic IPD. Samples from individuals with symptomatic IPD due to 12 different *PRNP* mutations were included in the study (P102L (26), 6OPRI (19), E200K (10), 5OPRI (7), D178N (6), A117V (5), 4OPRI (3), Y163X (3), E196K (1), P105L (1), Q212P (1), V210I (1)). Including a single sample (earliest available) for each individual, we compared plasma tau and NfL between mutations. Mutations typically causing a rapid CJD-like disease phenotype (E200K, 4OPRI, E196K, V210I) were associated with very high concentrations of both tau and NfL in plasma, similar to those seen in sCJD, while the D178N mutation (typically causing either a CJD-like or fatal familial insomnia phenotype) gave slightly lower concentrations. Mutations typically causing Gerstmann-Straussler-Scheinker syndrome (P102L, A117V, P105L) seemed to result in a modest increase in tau and a relatively marked (though more variable) increase in NfL. Mutations typically causing a relatively slow cognitive decline (5OPRI, 6OPRI) produced more modest elevations, similar to those seen in the AD and FTD groups, with whom their clinical presentations may overlap.



Supplementary Figure 3. Relationship of plasma tau and NfL to number of days from death in symptomatic IPD, including both cross-sectional and longitudinal datasets

Red continuous, dashed and dotted lines show 50th, 75th and 90th centiles of healthy controls respectively. Blue lines show the linear mixed effects model fits for each individual in the longitudinal dataset. Changes in plasma biomarkers with disease progression in IPD were also studied, using similar methods to those described above for sCJD. For plasma NfL, both the cross-sectional (baseline) data and the longitudinal data showed that concentration tends to increase as IPD progresses, and this was supported by linear mixed modelling (method as described for sCJD, but with *PRNP* mutation included as a covariate in place of *PRNP* codon 129).



Supplementary Figure 4. Relationship of plasma tau and NfL to number of days from death in iCJD and vCJD, including both cross-sectional and longitudinal datasets

Circles indicate samples from patients with vCJD, diamonds indicate samples from patients with iCJD. Red continuous, dashed and dotted lines show 50th, 75th and 90th centiles of healthy controls respectively. As for sCJD, the differences in plasma tau and NfL between diagnostic groups are summarised in Table 1, and in the box plots in Figure 1.



References

1. Wadsworth JDF, Adamson G, Joiner S, et al. Methods for Molecular Diagnosis of Human Prion Disease. *Methods Mol Biol* 2017; **1658**: 311-46.
2. Wadsworth JD, Hill AF, Beck JA, Collinge J. Molecular and clinical classification of human prion disease. *Br Med Bull* 2003; **66**: 241-54.
3. Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. *Brain* 2003; **126**(Pt 6): 1333-46.
4. Parchi P, de Boni L, Saverioni D, et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. *Acta Neuropathol* 2012; **124**(4): 517-29.
5. Mead S, Burnell M, Lowe J, et al. Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. *JAMA Neurol* 2016; **73**(4): 447-55.